Soleno Therapeutics (SLNO) Income from Continuing Operations (2013 - 2026)
Soleno Therapeutics (SLNO) reported Income from Continuing Operations of 31378000.0 for Q1 2026, up 171.68% year-over-year from 11549470.2 in Q1 2025, and down 27.63% quarter-over-quarter from 43358000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 14 years of Income from Continuing Operations data on file, last reported at 31378000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 31378000.0, up 171.68% year-over-year; the trailing twelve-month figure through Mar 2026 was 96041000.0 (up 148.51% YoY), and the FY2025 annual result was 20890000.0, up 111.88% from the prior year.
- Income from Continuing Operations eased to 31378000.0 in Q1 2026 per SLNO's latest filing, from 43358000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 43358000.0 in Q4 2025 and troughed at 76616000.0 in Q3 2024.
- A 5-year average of 10973764.71 and a median of 8356000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 650.55% in 2024, then soared 177.77% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 5610000.0 in 2022, then tumbled by 109.73% to 11766000.0 in 2023, then sank by 373.83% to 55751000.0 in 2024, then soared by 177.77% to 43358000.0 in 2025, then declined by 27.63% to 31378000.0 in 2026.
- Business Quant data shows SLNO's Income from Continuing Operations at 31378000.0 in Q1 2026, 43358000.0 in Q4 2025, and 26013000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.38 Mn |
| Dec 31, 2025 | 43.36 Mn |
| Sep 30, 2025 | 26.01 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Mar 31, 2025 | -43.77 Mn |
| Dec 31, 2024 | -55.75 Mn |
| Sep 30, 2024 | -76.62 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -21.40 Mn |
| Dec 31, 2023 | -11.77 Mn |
| Sep 30, 2023 | -10.21 Mn |
| Jun 30, 2023 | -8.48 Mn |
| Mar 31, 2023 | -8.36 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -6.24 Mn |
| Jun 30, 2022 | -6.78 Mn |
| Mar 31, 2022 | -5.77 Mn |
| Dec 31, 2021 | -3.00 Mn |
| Sep 30, 2021 | -8.29 Mn |
| Jun 30, 2021 | -11.09 Mn |